Company type | KGaA with Aktiengesellschaft as partner with unlimited liability |
---|---|
FWB: 1SXP | |
ISIN | DE000A3ENQ51 |
Industry | Healthcare |
Founded | August 1, 2022 |
Headquarters | Mainz, Germany |
Key people | Andreas Reisse, CEO Almuth Steinkühler, CFO |
Products | Pharmaceutical drug containment and delivery systems |
Revenue | €899 million (2022/2023)[1] |
Owner | Schott AG |
Number of employees | 4,646 (as of September 30, 2023)[1] |
Divisions |
|
Website | schott-pharma |
Schott Pharma (stylized as SCHOTT Pharma) is a provider of drug containment solutions and delivery systems for injectable drugs.[2] Headquartered in Mainz, Germany, the company operates in 14 countries.[3]
History[edit]
In 1887, Otto Schott developed borosilicate glass for technical applications. Starting in 1911, Schott manufactured borosilicate glass tubing for the production of pharmaceutical ampoules and vials.[4]
Schott Pharma was established as a standalone company in 2022 through a carve-out from Schott AG, a manufacturer of specialty glass and glass-ceramics.[5]
In September 2023, Schott Pharma went public on the Frankfurt Stock Exchange. With a value of €935 million, the IPO was the largest of the year in Germany.[6][7] In December 2023, Schott Pharma was included in the SDAX.[8]
Company Profile[edit]
The company is headquartered in Mainz and operates in 16 locations across 14 countries.[9]
The company is listed on the Frankfurt Stock Exchange's SDAX. The majority of its shares are held by Schott AG (as of 2023: 77%).[7]
Schott Pharma develops and manufactures drug containment solutions and delivery systems for injectable drugs, which it supplies to companies in the biotechnology and pharmaceutical industries.[10]
Its business is divided into two divisions:
- Drug Containment Solutions: pharmaceutical vials, cartridges, and glass ampoules
- Drug Delivery Systems: prefillable glass syringes and syringes made from Cyclic olefin copolymers (COC), suitable for deep-cold medications.[11]
References[edit]
- ^ a b SCHOTT Pharma Annual Report 2022/2023 (accessed February 08, 2024)
- ^ Kansteiner, Fraiser (2023-12-23). "Glass specialist Schott Pharma touts 2023 sales growth, Serbia expansion and hiring plans". Fierce Pharma. Retrieved 2024-04-08.
- ^ "Größter Börsengang in 2023: So hat sich die SCHOTT Pharma-Aktie seit ihrem IPO entwickelt - und so könnte es in 2024 nun weitergehen". finanzen.net. 2024-01-24. Retrieved 2024-02-28.
- ^ "Impfstoff-Ampullen – Rohrglas für Lebensretter - VBG Spezial". glaskeramik.org. VBG. 2021-07-04. Retrieved 2024-02-28.
- ^ Kansteiner, Fraiser (2022-01-08). "Glass maker Schott's pharma business sets out on its own. Will an IPO follow?". Fierce Pharma. Retrieved 2024-02-28.
- ^ Farr, Emma-Victoria; Mayo Cerqueiro, Pablo (2023-09-28). "Schott Pharma shares jump 16% in Frankfurt trading debut". reuters.com. Reuters. Retrieved 2024-02-28.
- ^ a b "Schott Pharma startet erfolgreich an der Börse". tagesschau.de. 2023-09-28. Retrieved 2024-02-28.
- ^ Ingerl, Christian (2023-12-13). "Profitabler Small Cap: Zulieferer Schott Pharma bald im SDax". Capital. Retrieved 2024-02-28.
- ^ "Größter Börsengang in 2023: So hat sich die SCHOTT Pharma-Aktie seit ihrem IPO entwickelt - und so könnte es in 2024 nun weitergehen". finanzen.net. 2024-01-24. Retrieved 2024-02-28.
- ^ SCHOTT Pharma Annual Report 2022/2023, SCHOTT Pharma, p. 14, retrieved 2024-02-28
- ^ "Schott Pharma rolls out pre-filled polymer syringes for deep-cold medication". NS Medical Devices. 2023-05-18. Retrieved 2024-02-28.